Viatris is spending a lot of money to buy Pacira, which makes non-opioid pain medicines.

Oct 8, 2026, 12:58 PM ETDealRead the original at Benzinga

Good for VTRS

Viatris’ $1.65 billion purchase adds 2 established pain treatments and is expected to lift its financial measures right away. It will use cash and short-term borrowing, and approvals remain, but the expected business gains support a positive reading.

VTRS · Viatris Inc.

AI read · Good for VTRS

The AI's read

The added treatments give Viatris more ways to sell non-opioid pain care, including products for surgery and knee pain. The company expects an immediate lift to its financial measures and sees room to cut costs and raise sales. It will use cash and short-term borrowing, and regulators and shareholders must still approve the deal. Those costs and conditions temper the expected gains, but the added products and expected profit support a positive reading.

PCRX · Pacira BioSciences Inc.

AI read · Good for PCRX

The connection

Pacira shareholders are set to receive $36.50 per share in cash. The deal still needs regulatory clearance and shareholder approval, so the payment depends on completion.

Get alerts for VTRS

Follow Viatris Inc. (VTRS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for VTRS

Free on the App Store and Google Play, or on the web.